IASLC Studying Impact of COVID-19 on International Lung Cancer Clinical Trial Enrollment, Mitigation Strategies
Joy CurzioAlthough clinical trials are vitally important to researchers working to improve therapies for lung cancer, clinical trials also provide what could be lifesaving treatments to those patients on trials. When […] Read more
Advancing Combined Modality Therapy for Early-Stage, Screen-Detected Disease: Adjuvant/Neoadjuvant Therapy
David Yankelevitz, MD+more
During the 17th annual Quantitative Imaging Workshop held in late Fall 2020, the Initiative for Early Lung Cancer Research on Treatment (IELCART) offered two sessions with panel discussions exploring the […] Read more
Differences in Smoking and Lung Cancer Incidence Among Black and White Young Adults in the United States
Robin Cornelissen, MD, PhDIn the United States, racial disparities in lung cancer incidence are known to exist. This is most likely caused by higher smoking prevalence among non-Hispanic Black adults compared to non-Hispanic […] Read more
Prolonging CT Screening Intervals is Deemed Safe in Individuals with Negative Baseline Results
In his May 7 presentation “Advance Lung Cancer Screening Globally,” Dr. Pastorino, co-chair of the CT Screening Symposium and director of the Thoracic Surgery Division at the Istituto Nazionale Tumori in Milan, discussed the MILD, BioMILD, and SMILE trials. He also is chair of the IASLC’s Screening and... Read more
Gouri Shankar Bhattacharyya, MD, FRCP, died this past week of COVID-19–related complications. A medical oncologist in Kolkata, India, with 25 years of experience, Dr. Bhattacharyya’s special interests were many and […] Read more
The Importance of Shared Decision Making: A Patient’s Perspective on Skin Toxicity with Afatinib/Cetuximab
Valerie AladieffAlthough the importance of multidisciplinary care teams is known, unfortunately, cross-specialty knowledge is not always solicited or recommended Read more
IASLC Establishes Global Molecular Database for Thoracic Malignancies: A Call for Data
Raymond U. Osarogiagbon, MBBS, FACPThe IASLC has established authority as the only global multidisciplinary organization dedicated to overcoming the four major thoracic malignancies- esophageal cancer, lung cancer, mesothelioma, and thymic malignancies. As we enter […] Read more
A National Network Provides a Window into Lung Cancer Screening Trends, Successes across the United States
Joy CurzioNow that the positive impact of lung cancer screening on mortality and morbidity is irrefutable, there is an obvious need to find new ways to overcome consistent challenges with implementation […] Read more
Christian Rolfo, MD, PhD, will take the reins as associate director for clinical research in the Center for Thoracic Oncology/Tisch Cancer Institute, Mount Sinai, New York. Previously, Dr. Rolfo served […] Read more
Olaparib Maintenance Did Not Improve PFS, OS in Platinum-Sensitive NSCLC
Leah LawrenceThe PARP inhibitor olaparib did not improve PFS or OS compared with placebo when used as a maintenance therapy for patients with platinum-sensitive NSCLC, according to results of the phase […] Read more